ISPOR CEO Rob Abbott Advocates for HEOR in Global Healthcare Decision Making

By HEOR Staff Writer

November 9, 2023

Global Healthcare Decision Making

Understanding the Importance and Scope of HEOR in Today’s Healthcare Landscape

The Professional Society for Health Economics and Outcomes Research (ISPOR) is a global non-profit organisation. It promotes the use of health economics and outcomes research (HEOR) in medical care decision-making. Recently, CEO Rob Abbott discussed the organisation’s objective, the importance of HEOR, and the future of healthcare. 

ISPOR’s membership is comprised of individuals from academia, industry, patient groups, and payers. These individuals come from 110 different countries. This organisation’s work would not be possible without its broad membership. This guides debates and conversations by offering a variety of perspectives.

 Abbott stressed the crucial role of HEOR in today’s world, particularly in overburdened healthcare systems. HEOR offers valuable data and insights, aiding tough decisions in the healthcare sector. It helps achieve superior results at lower costs.

In addition, Abbott clarified the differences between HEOR and health technology assessment (HTA). Compared to HEOR, which includes a wider field of research and incorporates notions such as real-world evidence, real-world data, and patient participation, HTA primarily concentrates on the effectiveness of a particular technology.

The CEO also discussed the potential and difficulties that will exist in the healthcare industry in the year 2030. Some of these problems and opportunities include the concept of whole health, as well as affordability and sustainability. He stressed the significance of scientific rigor and evidence in the process of guiding decisions and policies pertaining to healthcare.

ISPOR’s Role in Emerging Markets and the Incorporation of Patient Perspectives in Healthcare

The function of ISPOR in developing markets was on the table. These markets are experiencing an acute shortage of practicable health economic models. ISPOR has regional chapters in over one hundred countries. The majority of which are either economies in transition or countries with low or middle incomes. The organisation is providing substantial assistance in the form of active support for the development of HEOR capacity and its use in these regions.

Lastly, Abbott discussed the significance of incorporating the viewpoints and preferences of patients into the decision-making processes that take place inside the healthcare system. ISPOR has long been dedicated to achieving this objective. In order to ensure that the patient voice is heard, the organisation has formed patient roundtables and a special interest group.

Global Healthcare Decision Making

Abbott concluded his speech by emphasising ISPOR’s dedication to incorporating HEOR into decision-making. Their goal is to improve health outcomes at a more affordable cost. He invited anyone interested in HEOR or enhancing the accessibility, equity, and impact of healthcare systems on patients, to join ISPOR. 

Reference url

Recent Posts

large language models
Large Language Models in Evidence-Based Medicine

By João L. Carapinha

July 3, 2026

Large language models deliver rapid synthesis of medical literature, but according to research on fast information and slow evidence, they cannot independently generate validated evidence for clinical decisions. These tools sit at a...
African Pharmacogenomic Integration
African Pharmacogenomic Integration Enhancing Essential Medicine Prescribing in Africa

By João L. Carapinha

July 3, 2026

African Pharmacogenomic Integration has become an urgent policy priority, with evidence showing that more than 10 percent of essential medicines across Africa require genetically guided prescribing to prevent harm and improve outcomes in diverse populations. Current dosage guidelines for HIV, ...
pharmaceutical manufacturing affordability
Pharmaceutical Manufacturing Affordability as a Key to South Africa’s Local Production Goals

By João L. Carapinha

July 3, 2026

Pharmaceutical manufacturing affordability remains the decisive factor in South Africa’s efforts to build domestic capacity for essential medicines and vaccines. Government, industry and research leaders who met at the TIPS Development Dialogue on 17 June made clear that economic barriers to acce...